新华制药:OAB-14干混悬剂完成Ⅱ期临床中国首例患者入组

国际金融报
19 Jun

新华制药公告,治疗轻至中度阿尔茨海默病的OAB-14干混悬剂已完成Ⅱ期临床中国首例患者入组。OAB-14干混悬剂Ⅱ期药物临床试验由首都医科大学宣武医院联合全国多中心共同参与,于2025年6月19日完成中国首例患者入组。OAB-14是新华制药与沈阳药科大学合作研制的具有自主知识产权的新化学结构创新药,属于1类创新药。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10